Hepatitis C virus transmission among HIV-infected men who have sex with men:

Modeling the effect of behavioral and treatment interventions

Luisa Salazar-Vizcaya^{1,3} (luisapaola.salazarvizcaya@insel.ch), Roger D Kouyos²

- (Roger.Kouyos@usz.ch), Cindy Zahnd¹ (cindy.zahnd@ispm.unibe.ch), Gilles Wandeler¹³ (gilles.wandeler@ispm.unibe.ch), Manuel Battegay⁴ (manuel.battegay@usb.ch), Katharine Elizabeth Ana Darling⁵ (Katharine.Darling@chuv.ch), Enos Bernasconi⁶
- (Enos.Bernasconi@eoc.ch), Alexandra Calmy⁷ (Alexandra.Calmy@hcuge.ch), Pietro
- Vernazza⁸ (pietro.vernazza@kssg.ch), Hansjakob Furrer³ (hansjakob.furrer@insel.ch),
- Matthias Egger¹⁹ (matthias.egger@ispm.unibe.ch), Olivia Keiser*¹
- (olivia.keiser@ispm.unibe.ch), Andri Rauch*³(Andri.Rauch@insel.ch), and the Swiss HIV Cohort Study
- ¹Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
- ²Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich,
- Zurich, Switzerland
- ³Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- ⁴Division of Infectious Diseases and Hospital Epidemiology University Hospital Basel, Basel, Switzerland
- ⁵Infectious Diseases Service, Department of Medicine, University Hospital and University of
- Lausanne, Lausanne, Switzerland
- ⁶Division of Infectious Diseases, Lugano Regional Hospital, Lugano, Switzerland
- ⁷Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland
- ⁸Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/hep.28769

⁹ Centre for Infectious Disease Epidemiology & Research (CIDER), University of Cape

Town, Cape Town, South Africa

*contributed equally to this manuscript

Keywords: HCV; MSM; mathematical model; DAAs; sexual behavior.

Acce

Hepatology

Correspondence to: Olivia Keiser olivia.keiser@ispm.unibe.ch Tel: +41 31 631 35 15 Fax: +41 31 631 35 20, ISPM, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland.

Abbreviations: hepatitis C virus (HCV); men who have sex with men (MSM); Swiss HIV Cohort Study (SHCS); direct-acting antiviral agents (DAAs)

Financial support: This study has been financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (SNF grants #148522 and #146143).

Accepted

Hepatology

Abstract

The incidence of hepatitis C virus(HCV) infections among HIV-infected men-who-have-sexwith-men(MSM) increased in recent years and is associated with high-risk sexual behavior. Behavioral interventions that target high-risk behavior associated with HCV transmission and treatment with direct-acting antivirals(DAAs) may prevent further HCV infections. We predicted the effect of behavioral and treatment interventions on HCV-incidence and prevalence among HIV-infected MSM up to 2030 using a HCV transmission model parameterized with data from the Swiss HIV Cohort Study. We assessed behavioral interventions associated with further increase, stabilization and decrease in the size of the population with high-risk behavior. Treatment interventions included increase in treatment uptake and use of DAAs. If we assumed that without behavioral interventions high-risk behavior spread further according to the trends observed over the last decade, and that the treatment practice did not change, HCV-incidence converged to 10.7/100 person-years(py). All assessed behavioral interventions alone resulted in reduced HCV transmissions. Stabilization of high-risk behavior combined with increased treatment uptake and the use of DAAs reduced incidence by 77% (from 2.2 in 2015 to 0.5/100 py) and prevalence by 81% (from 4.8% in 2015 to 0.9%) over the next 15 years. Increasing treatment uptake was more effective than increasing treatment efficacy to reduce HCV-incidence and -prevalence. A decrease in high-risk behavior, led to a rapid decline in HCV-incidence, independent of treatment interventions. Conclusion: Treatment interventions to curb the HCV epidemic among HIV-infected MSM are effective if high-risk behavior does not increase as it has during the last decade. Reducing high-risk behavior associated with HCV transmission would be the most effective intervention for controlling the HCV epidemic, even if this was not accompanied by an increase in treatment uptake or efficacy.

Hepatology

The HCV epidemic in HIV-infected patients has evolved quickly over the past few years(1-4). In western countries, HCV is increasingly transmitted among HIV-infected men who have sex with men (MSM)(1, 5-9). We observed, in the Swiss HIV Cohort Study (SHCS)(10), a steep rise in incidence of HCV infections among MSM without history of injection drug use. In contrast, HCV incidence stabilized among heterosexuals, and decreased among people who inject drugs(3).

An international network of HCV transmission among HIV-infected MSM was revealed by a phylogenetic study(11). In this population, transmission is associated with high-risk behavior including condomless traumatic anal intercourse, fisting, use of recreational drugs, and group sex(1, 3, 7, 12, 13). In the SHCS, the increase in HCV incidence coincided with reduced self-reported condom use among MSM on antiretroviral therapy (ART)(14).

Effective interventions to curb the HCV epidemic among HIV-infected MSM remain to be established. Behavioral interventions that target high-risk sexual practices associated with HCV transmission may prevent new HCV infections. Because recently introduced treatments for HCV with second generation direct-acting antiviral agents (DAAs) rapidly reduce HCV viral load and achieve high cure rates, they offer an unprecedented opportunity to prevent transmissions.

In this study, we analyzed data from the SHCS to develop a mathematical model of HCV transmission among MSM who do not inject drugs. We used the model to replicate the HCV epidemic in Switzerland and to estimate the effect of behavioral and treatment interventions on HCV incidence and prevalence up to 2030.

Hepatology

6

Subjects and Methods

The Swiss HIV Cohort Study

The SHCS is a nationwide, prospective cohort that enrolls HIV-infected patients, aged 16 or older, since 1988, drawing from Swiss university hospitals, cantonal reference hospitals and private practices(10, 15). Written informed consent is mandatory for inclusion in the SHCS, and the study has been approved by all local ethical committees. The SHCS includes 73% of HIV-infected patients declared to the Swiss public health authorities (16). Clinical, behavioral and laboratory data are collected at enrolment and at follow-up visits every six months. The collected data include information on antiretroviral and HCV treatments, sexual preferences, condom use and sex with stable and occasional partners(15). HCV-seronegative patients were screened biannually for HCV infection between 1998 and 2006, and yearly thereafter. Immunoblotting confirmed positive results by third-generation enzyme-linked immunoabsorbent assay (ELISA). We included all HCV-seronegative MSM who had at least one follow-up HCV antibody measurement after January 2000. Patients with a positive HCV serology at entry, those who seroconverted before 2000, and those who reported injecting drug use during the follow-up period, were excluded from the incidence analysis. For the estimation of the incidence that we used to fit the model, the follow-up period ended at the

first positive HCV serology or last negative serology as previously described(3). For the analyses on sexual behavior, the follow-up period ended at drop-out or death.

Hepatology

7

HCV transmission model

We adopted a system of ordinary differential equations to model HCV transmission among HIV-infected MSM (Supplementary Material). We set out to reproduce HCV incidence among HIV-infected MSM in Switzerland between 2000 and 2013 by classifying the population into compartments distributed by stage of infection, risk groups and enrolment in care. Risk groups included: i) Individuals who do not engage in sexual practices associated with HCV transmission (group without high-risk behavior) and ii) Individuals who do engage in sexual practices associated with HCV transmission (group with high-risk behavior). Each risk group includes five compartments: 1) two HCV-uninfected (Susceptible, S) "in" and "out" of HIV care (referred as to in-care and out-of-care from now on); 2) two HCV-infected (Infected: I) "in" and "out" of care; and, 3) one on treatment for HCV (on Treatment, T) only accessible for individuals in-care. The model structure is summarized in Figure 1. Out-of-care individuals can enter the in-care category at a rate $\omega(t)$. Newly HIV-infected MSM enter the out-of-care susceptible category at a rate that varies over time $\rho(t)$. A fraction $\varphi \psi(t)$ of these individuals enter the susceptible compartment in the high-risk group, where $\psi(t)$ is the proportion of newly HIV-infected MSM who have unprotected sex with occasional partners, which we term unsafe sex, and φ is the proportion of these individuals who also engage in high-risk behavior and therefore at risk of HCV transmission. High-risk behavior comprises condomless traumatic anal intercourse, fisting, use of recreational drugs, and group sex. φ is referred to as *high-risk/unsafe sex ratio*. The remaining newly HIV-infected MSM enter the susceptible compartment in the group without high-risk. Individuals switch from the group without high-risk to the high-risk group at a rate $\varphi\sigma(t)$, where $\sigma(t)$ is the rate at which individuals start to have unsafe sex. We refer to $\psi(t)$ and $\sigma(t)$ as high-risk recruitment *parameters*. All susceptible individuals may be infected by an external force of infection λ that accounts for infections unrelated to high-risk contacts within the modeled population.

Hepatology

8

Because λ affects all individuals, incidence is always $\geq \lambda$ irrespective of interventions. Individuals within the high-risk group infect each other at an *infection rate* β . This rate is associated with the probability of establishing an infection given an infectious contact. Infected individuals in both risk groups start treatment at a rate $\gamma(t)$. The mean duration of treatment is $1/\eta$ and results in HCV clearance for a fraction α of treated individuals. Individuals who clear the infection are again susceptible. Individuals exit the system at a rate μ from all compartments, which indicates the end of their sexual activity in Switzerland. We accounted for reinfections and naïve infections by splitting this model. The resulting model ("reinfection model") is equivalent to the main one and its structure is displayed in Figure S1.

Model parameterization

Most parameters were measured from SHCS data. The *high-risk/unsafe sex ratio* φ , the proportion of individuals out-of-care and the change in diagnosis rate over calendar year were estimated from published data, the *infection rate* β and *the assortativity coefficien* were fitted to the incidence data by Maximum Likelihood (Supplementary Material).

We obtained the numbers of newly susceptible individuals $\rho(t)$ from the SHCS database and the proportion of HIV-infected MSM out of the SHCS. These numbers were based on new registrations into the cohort. We used Bayesian Poisson regression models(17, 18) to estimate entrance rates from these numbers. HCV treatment rates were determined separately for the periods 2000-2005 and 2006-2013, since treatment uptake substantially increased between those periods in the SHCS(19). We modeled this transition as a logistic function (see Supplementary material). Initial conditions were also approximated from data, namely the numbers of patients susceptible, infected, and on treatment for HCV at the beginning of 2000. We used SHCS information on self-reported unprotected sex with occasional partners to estimate two time-dependent *high-risk recruitment parameters: i*) the proportion of patients

Hepatology

who reported unsafe sex $\psi(t)$ during their second follow-up visit, which we consider to reflect their sexual behavior following HIV-diagnosis; and *ii*) the rate $\sigma(t)$ at which patients without unsafe sex at the begging of the follow-up, started to engage in this practice.

We estimated the percentage of patients out-of-care by combining data from the European men-who-have-sex-with-men Internet survey (EMIS) (20) and a modeling study on HIV transmission among MSM in Switzerland (21). We found transition rates from HIV-infection to enrolment in care that led the model to reproduce this proportion by assuming that this rate reflected the increase estimated in(21).

Uncertainty analyses were based on Latin Hypercube sampling. We sampled the transmission rate β , the exit rate μ and the external force of infection λ and produced combinations of these parameters using this technique. We then obtained model solutions for each combination to determine 95% confidence intervals (Supplementary Material).

Interventions to reduce high-risk behavior and treatment scenarios

We projected future HCV incidence based on hypothetical interventions that reduce high-risk behavior and increase treatment uptake and/or efficacy. Projections of the *high-risk recruitment parameters* were based on observed trends. Behavioral interventions included three scenarios: 1)Pessimistic scenario: no intervention, in which the size of the high-risk group grows further according to the trend observed in the SHCS over the last decade. In this scenario an increasing number of patients enter the high-risk group, until *high-risk recruitment parameters* duplicate the last observation; thereafter they saturate; 2)Intermediate scenario: health promotion or autonomous saturation leading to a stable size of the high-risk group. 3)Optimistic scenario: health promotion or autonomous saturation leading to a decreasing size of the high-risk group. In this scenario, no more patients enter the high-risk

Hepatology

10

category. Treatment interventions included use of DAAs and increased treatment uptake. We considered two scenarios for treatment uptake, according to the percentage of infected patients treated per year (treatment rate): 1) treatment uptake remained constant at the observed average between 2006 and 2013 (22% per year); and, 2) increased to 100% per year; i.e., the average time from infection to treatment was reduced to one year. Our model also compared the impact of DAAs(22, 23) with interferon-based treatments(24). The average duration of interferon-based treatment was assumed to be 9 months and to result in 53% sustained virologic response (SVR), as observed in the SHCS(19). Treatment with DAAs was assumed to last 3 months on average, and to result in 90% SVR, independent of HCV genotype(22, 23). We reported predicted incidence and prevalence curves by combining these scenarios.

In a further analysis, we assessed a best-case scenario of risk behavior. In this analysis we accelerated the decrease in the size of the high-risk group associated with the optimistic scenario. We assumed that individuals in the high-risk group transit to the group without high-risk at a rate that equals the last observed rate of transition from the group without to the group with high-risk behavior. This approximation aims to reflect the speed of behavioral change observed in the population.

Sensitivity analysis I: Different high-risk/unsafe sex ratios

The approximated value for the *high-risk/unsafe sex ratio* that we used in the main analyses (0.25 as observed in(13)) may not accurately reflect the reality as it does not include all sexual practices leading to HCV transmission. We therefore performed model fits and projections for all scenarios, where this ratio increased in steps of 0.05 from 0.2 to 0.4.

Sensitivity analysis II: Imported infections

Hepatology

In this analysis we assumed that an increasing percentage of incident HCV infections observed in the high-risk group where not acquired by contact with other HIV-infected MSM in Switzerland (imported infections). We performed model fits and projections for all scenarios, where the percentage of imported infections increased from 3% to 27%. These values were achieved by assuming increasing external forces of infections λ in the high-risk group.

Sensitivity analysis III: Protective effect of previously cleared HCV infection

Some studies suggest that the risk of reinfection after clearance may be lower than the risk of infection in naïve individuals (25). We assessed the effect of this potential protective effect by assuming that the probability of HCV transmission given an infectious contact is lower in individuals who have cleared HCV than in naïve individuals. We performed model fits and projections for all scenarios, where the probability of reinfection was reduced by 13%, 25% (as in (26)) and 50%.

All procedures, including calibration, fitting algorithms and uncertainty analyses were implemented in R(27). Differential equations were solved with the R package deSolve(28,

Hepatology

Results

Study population

A total of 5,052 MSM were included in the analyses (Table 1). Median age at registration in the SHCS was 37 years [interquartile range (IQR) 31–44]. Ninety-one percent of all patients started ART during the follow-up time. Sex with occasional partners was reported by 3,860(76%) MSM, of whom 1,860(48%) also reported inconsistent condom use.

Model parameter estimates

Model parameters used to reproduce observed HCV incidence in the SHCS are shown in Table 2. An average of 190 HCV-negative MSM newly diagnosed with HIV and without history of intravenous drug use were enrolled into the cohort per year (Supplementary Figure S2A). The proportion of patients who reported unsafe sex during their second follow-up visit was 5% in 2000 and increased continuously to reach 13% in 2013 (Figure 2A). The transition rate to unsafe sex rose from 0.05 per year in 2000 to 0.13 per year in 2012 (Figure 2B). We assumed that a fraction 0.25 of patients who engage in unsafe sex engage in high-risk behavior. This approximation reflects the ratio between the number of patients who reported frequent bondage, dominance/submission, sadism/masochism (BDSM) or fisting and those who reported unprotected anal intercourse with non-steady partners in(13). The percentage of patients treated for HCV was 11% before 2006, and rose to 42% between 2006 and 2013. Consistently, when we compared the periods 2000-2005 and 2006-2013, average treatment rate increased by a factor of 10: 2% per year in the earlier period versus 22% per year in the later period (Table 2). Finally, the exit rate estimated from patients who died or left Switzerland, as specified in the cohort, was 0.049 (95% CI: 0.045-0.053), which implies an average time of over 20 years of sexual activity. We estimated that on average 84% HIV-

Hepatology

infected MSM were in care between 2000 and 2010. Associated rates of enrollment in care were found to be 0.45/year and 0.58/year. These rates imply times from HIV-infection to enrolment in care of 2.2 and 1.73 years respectively. Figure S3 shows the likelihood curve for the estimated rate of infection.

Observed and modeled HCV incidence, 2000-2013

Modeled HCV incidence accurately reproduces observed HCV incidence (Figure 2C). It increased from 0.2/100 person-years (py) in 2000 to 1.0/100 py in 2013.

Impact of interventions to reduce high-risk sexual behavior and treatment scenarios, 2015-2030

Pessimistic scenario: growing size of the high-risk group

If the spread of high-risk practices associated with HCV transmission was unchecked, the model predicted a steep increase in HCV incidence and prevalence. Incidence converged to 10.7/100 py if treatment practice remained unchanged (upper panel Figure 3A). If treatment uptake increased considerably, incidence continued to rise at a lower rate than with the current treatment practice, to reach 10.4/100 py and 8.5/100 py in 2030 with and without DAAs respectively (upper panel Figure 3A). Interestingly, the highest predicted incidence was observed in the scenario with current treatment uptake and DAAs. A combination of two factors explains this behavior: Firstly, short duration effective treatments lead to rapidly cured infections, which in turn results in an enlarged size of the susceptible group; and secondly, the treatment rate is not large enough to contain transmission. This outcome is observed in all scenarios.

13

Hepatology

14

Prevalence also increased rapidly in this scenario. Without change in treatment uptake, it was above 36% in 2030 irrespective of the type of treatment. But if treatment uptake increased considerably, prevalence in 2030 was 23.1% and 11% without and with DAAs respectively (lower panel Figure 3A). The model also predicted that in 2030 reinfection will account for at least 44% of all incident infections (versus 3.6% in 2015; Table S1)

Intermediate scenario: stable size of the high-risk group

Stabilization of high-risk behavior without change in treatment uptake led to a rapidly saturated incidence at around 2.6/100 py if treatment uptake did not change. If treatment uptake increased considerably, DAAs led to a continuous decline in incidence, reaching 0.5/100 py in 2030 (upper panel Figure 3B). The benefit of DAAs compared to interferon-based therapy was largest in this case. Prevalence displayed a similar pattern. It stabilized at around 12.7% if treatment uptake did not change, and decreased considerably to reach 0.9% at the highest treatment uptake with DAAs (lower panel Figure 3B). The model also predicted that in 2030 reinfection will account for at least 23% of all incident infections (Table S1).

Optimistic scenario: decreasing size of the high-risk group

A reduction in the frequency of high-risk practices associated with HCV transmission led to an immediate decrease in incidence, regardless of treatment uptake and type of treatment (upper panel Figure 3C). In this scenario, introducing DAAs had only a modest influence on incidence and prevalence. As expected, the minimal incidence and prevalence predicted in this study were achieved in this scenario when DAAs were introduced at the highest treatment uptake (incidence: 0.2/100 py, prevalence: 0.4% in 2030). The model predicted that in 2030 reinfection will account for at least 7.6% of all incident infections (Table S1).

Hepatology

Best-case scenario: rapidly decreasing size of the high-risk group

In this scenario, the model predicted an immediate steep decline in HCV incidence (upper panel Figure 4A). In 2025 incidence saturated at 0.2/100 py irrespective of treatment interventions. Prevalence also declined considerably in this scenario. In ranged between 2.5% and 0.4% in 2030 (lower panel Figure 4A).

Figure 4B shows HCV incidence and prevalence associated with different scenarios of highrisk behavior when assuming treatment with DAAs and current treatment rate. In all scenarios, incidence was more sensitive to the considered changes in treatment uptake than to changes in treatment efficacy (Figure 3). Trends for *high-risk recruitment parameters* in the first two behavioral scenarios are displayed in Figure S4. Table S2 shows changes in high-risk behavior associated with each scenario.

Sensitivity analysis I: Different high-risk/unsafe sex ratios

Projected HCV incidences with all interventions assuming increasing *high-risk/unsafe sex ratios* (i.e., increasing the proportion of patients with unsafe sex who also engage in high-risk behavior) are shown in supplementary Figure S5. In the pessimistic case scenario of risk behavior, the model predicted higher incidence and prevalence with increasing *high-risk/unsafe sex ratios*. Incidence in 2030 ranged from 8.2/100 py to 20.5/100 py and prevalence from 10.6% to 51.2% . with a ratios of 0.2 and 0.4 respectively (left panels Figure S5). Consistently, in the intermediate and optimistic scenarios of risk behavior, predicted incidence stabilized at higher values as *high-risk/unsafe sex ratios* increased (center and right panels Figure S5). Despite these differences, the effect of all intervention was equivalent to that described in the main analysis.

Hepatology

Sensitivity Analysis II: Imported infections

Behavioral and treatment interventions were also effective at decreasing HCV incidence and prevalence when the proportion of infections assumed to be imported increased. When this proportion was set to be maximum (27%) in the intermediate scenario of risk behavior, increased treatment uptake and efficacy led to incidence and prevalence to reach 0.7/100 py and 1.1% in 2030 respectively (Table S3). The goodness of the fit decreased as more infections observed in the high-risk group were assumed to be imported, suggesting a predominate role of domestic transmission. Worsening fits may lead to unrealistic projections, especially in the pessimistic scenario because the model becomes less capable of reproducing the observed increase in incidence.

Sensitivity Analysis III: Protective effect of previously cleared HCV infection

Predicted HCV incidence and prevalence decreased as the reduction in reinfection probability increased (Table S4). Incidence and prevalence displayed the same pattern observed in the main analysis (Figure S6). In the pessimistic scenario, with a 25% reduction in reinfection probability, treatment with DAAs at the highest treatment uptake led to 5.5/100 py incidence (versus 8.5/100 py in the main analysis) and 7.6% prevalence (versus 11.0% in the main analysis). Despite these variations, the effect of all intervention was equivalent to that described in the main analysis, even when the protective effect was strong.

17

Discussion

We reconstructed the HCV epidemic among HIV-infected MSM in Switzerland between 2000 and 2013 using a mathematical transmission model based on two risk groups. We used this model to predict the future course of HCV incidence and prevalence in HIV-infected MSM. Different modeled scenarios based on hypothetical behavioral and treatment interventions showed that prevention of high-risk behavior alone could result in considerably reduced HCV transmission.

The model showed that substantially increasing only treatment uptake would more effectively reduce HCV incidence and prevalence than substantially increasing only treatment efficacy. There are fewer contraindications to DAAs-based treatments than to interferon-based treatments, so DAAs-based treatments may improve uptake. The model predicts that if highrisk behavior continues to increase according to the trends observed during the last decade, HCV incidence will continue to rise, despite increasing treatment uptake and efficacy. However, stabilization of high-risk behavior combined with a considerable increase in treatment uptake and efficacy could effectively reduce HCV incidence and prevalence. Moreover, the benefit of DAAs over IFN-based therapy was highest in this stable scenario when assuming high treatment uptake. Reduction in high-risk behavior could lead to a rapid decline in incidence within the next few years, independently of improved treatment uptake or efficacy. The model predicted that reinfections will account for an increasing proportion of all incident infections in the future. This is in line with recent studies that reported high rates of reinfection (30)(31).

Hepatology

Strengths and limitations

A major strength of our analysis is that we estimated most model parameters directly by using patient level data from the SHCS(10, 15). Most parameters corresponded to a single population, so they were internally consistent. The inclusion of data on the evolution of sexual behavior among HIV-infected MSM over the last decade was an additional strength of our model. This data reveal heterogeneity(32), which we captured by splitting the population into two risk behavior groups.

Due to the lack of data on specific high-risk practices, we had to assume that the proportion of people with high-risk behavior was a constant fraction of the population that engages in unsafe sex. We believe this is a reasonable approximation to reality which allowed us to take advantage of the available data on sexual behavior. This quantity was based on published observations(13) which may have led to an underestimation of this fraction as it does not include all practices that are believed to result in HCV transmission. However, a sensitivity analysis which considered several values of this parameter, resulted in concordant predictions. Another limitation was that we did not explicitly model the link between sexual behavior and recreational intravenous drug use, which is increasingly recognized as a risk factor for HCV transmission among MSM(12, 33) and may contribute to the HCV epidemic. We did not include HIV-uninfected MSM in the modeled population, but we think this was reasonable: a recent Swiss survey showed that the prevalence of HCV in HIV-uninfected MSM was only 0.4%, thus not higher than in the general population (34). Our approximation was based on the fact that there is no evidence of boosted HCV transmission among HIV-negative MSM. The reason why HCV transmission seems to be confined to HIV-infected MSM is unknown. Serosorting (the practice of using HIV status as a decision-making point in choosing sexual partners) is common, but not generalized (35) and its role in the spread of HCV among HIV-

Hepatology

infected MSM remains uncertain. Further factors including HIV-mediated impairment of mucosal immunity which is often not completely restored during ART may also play a role. Importantly, the scale-up of HIV pre-exposure prophylaxis may reduce serosorting, which in turn could result in an HCV transmission bridge from HIV-positive to HIV-negative MSM.

Little is known about risk behavior patterns and demographics of people with undiagnosed HIV infections. However, 80% of HIV-infected MSM living in Switzerland are estimated to be enrolled in the SHCS (16). Therefore, the data we used to parameterize this model is likely to be representative for this population.

The main model assumed a constant external force of infection. Although the frequency of drugs injection among MSM in the SHCS was low (only 2.5% ever reported) and stable over the study period (results not shown), which supports our assumption, we undertook a sensitivity analysis to evaluate the impact of increasing the external force of infection in the high-risk group. These increases are equivalent to more infections acquired by high-risk contacts outside the modeled population (imported infections). The model predictions suggested that behavioral and treatment interventions can effectively reduce incidence and prevalence even when the number of imported infections is large. Our conclusions also remained unchanged when assuming that HCV clearance reduces the risk of subsequent infections (protective effect). In this study, we did not explore alternative explanations for increased HCV transmissions over time, such as the emergence of more transmissible HCV strains. However, previous phylogenetic analyses revealed that many different HCV strains were involved in its spread among HIV-infected MSM(11, 36), so the emergence of a particularly transmissible HCV strain is unlikely to be the main driver of the epidemic. Finally, assuming that risk behavior will continue to increase at the speed it has over the last years (as we did in the pessimistic scenario) may have led to unrealistically large sizes of the population with high-risk behavior and resulted in a very high prevalence for the pessimistic

Hepatology

This article is protected by copyright. All rights reserved.

19

20

scenario. This and the best-case scenario are extreme cases that bound the possible future outcomes of the HCV epidemic. Our results may not apply to populations of HIV-infected MSM where HCV incidence has not increased, since these populations may not have the same demographic, clinical and behavioral characteristics (37) as the population we studied. But HCV incidence has recently increased among HIV-infected MSM in many settings as synthesized in a meta-analysis (9).

In this study, we did not use viral sequence data to trace HCV transmissions. A recently published phylogenetic analysis in the SHCS(38) revealed that people with closely related HIV viruses were more likely to acquire HCV infection if their phylogenetic-neighbours were HCV-infected. These HIV and HCV transmission networks within the SHCS underscore the role of domestic HCV transmission linked to sexual risk behavior. Therefore, public health interventions might reduce HCV transmission even if these are only implemented locally.

Comparison with other studies

We believe ours is the first published modeling study to (i) use data on changes in high-risk behavior to account for changes in HCV incidence among HIV-infected MSM, (ii) to evaluate the effects of trends in high-risk behavior on the course of the HCV epidemic, independent of treatment intensification, and (iii) to incorporate longitudinal data on sexual behavior and routine HCV screening together with HCV treatment uptake and outcomes. Martin et al. (39) recently modeled the HCV epidemic among HIV-diagnosed MSM in the UK and found that scaling-up DAAs in this setting could substantially reduce HCV prevalence without behavioral interventions, but Martin et al studied a population with stable primary HCV incidence, while primary HCV incidence has increased in the SHCS and in other settings over the last decade (3)(9). Martin et al did not include data on the evolution of high-risk behavior

Hepatology

or assess the role of changing high-risk behavior, independent of treatment intensification. Because changes in high-risk behavior drive the surging HCV epidemic and are a key target for interventions, we based our predictions on potential scenarios of high-risk behavior. In contrast with the study by Martin et al, our results suggest that in settings where HCV incidence is rising, scaling-up treatment cannot revert the HCV epidemic if high-risk behavior continues to spread as it has over the last decade.

Implications of Findings

Our model suggests that the most effective strategy for controlling the HCV epidemic among HIV-infected MSM is to adopt health promotion interventions that limit high-risk behavior. Targeted interventions to curb the HCV epidemic, such as increasing access to treatment, are effective if accompanied by interventions or autonomous saturation that slow the spread of high-risk behavior. Of note, self-reported unsafe sex does not reflect all high-risk sexual practices associated with HCV transmission that are not recorded in the SHCS. Self-reported unsafe sex rather served as a proxy for high-risk behavior. The good fit of the model predictions to the incidence data suggests that self-reported unsafe sex is associated with other high-risk sexual practices. Trends in self-reported unsafe sex might therefore predict the future course of HCV infections and guide interventions to reduce HCV incidence. The results of this study could be used to inform public health policy intended to prevent HCV transmission among HIV-infected MSM.

The validity and scope of our findings must be determined in clinical trials or observational studies. These model projections are based on hypothetical representative outcomes of interventions to reduce high-risk behavior (pessimistic, intermediate, optimistic and best), but real world interventions are likely to cluster around the intermediate scenario. Cost-effectiveness analyses that consider realistic outcomes for behavioral interventions are also

Hepatology

required to guide implementation of public health interventions intended to reduce

transmission of HCV among HIV-infected MSM.

Acce

Hepatology

References

- Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr PE, Bucher HC, Vernazza P, et
 al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men
 who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005;41:395-402.
- 2. Gotz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de Zwart O. A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. AIDS 2005;19:969-974.
- Wandeler G, Gsponer T, Bregenzer A, Gunthard HF, Clerc O, Calmy A, Stockle M, et
 al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic.
 Clin Infect Dis 2012;55:1408-1416.
- 4. van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chene G, Dorrucci M, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology 2013;144:751-760 e752.
- 5. Danta M, Rodger AJ. Transmission of HCV in HIV-positive populations. Curr Opin HIV AIDS 2011;6:451-458.
- 6. Vogel M, Boesecke C, Rockstroh JK. Acute hepatitis C infection in HIV-positive patients. Curr Opin Infect Dis 2011;24:1-6.
- 7. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, Fisher M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007;21:983-991.
- 8. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, van der Meer JT, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007;196:230-238.

Hepatology

9. Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS 2015;29:2335-

2345.

10. The Swiss HCV Cohort Study, URL: www.shcs.ch. [Accessed 10 April 2014].

- 11. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, Vogel M, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009;136:1609-1617.
- 12. Daskalopoulou MR, A., Phillips, A.; Sherr, L.; Speakman, A.; Collins, S.; Elford, J.; Johnson, MA.; Gilson, R.; Fisher, M.; Wilkins, E.;Anderson, J.; McDonnell, J.; Edwards,
- S.;Perry, N.; O'Connell, R.; Lascar, M.; Jones, M.; Johnson, AM.; Hart, G.; Miners, A.; Geretti, A-M.; Burman, W.; Lampe, FC. Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the crosssectional ASTRA study. The lancet HIV 2014;1: e22 - e31.
- 13. Schmidt AJ, Rockstroh JK, Vogel M, An der Heiden M, Baillot A, Krznaric I, RadunD. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men fromGermany--a case-control study. PLoS One 2011;6:e17781.
- 14. Hasse B, Ledergerber B, Hirschel B, Vernazza P, Glass TR, Jeannin A, Evison JM, et al. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2010;51:1314-1322.
- Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 2010;39:1179-1189.
 Kohler P, Schmidt AJ, Cavassini M, Furrer H, Calmy A, Battegay M, Bernasconi E, et
- al. The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. AIDS 2015;29:2509-2515.
- 17. Rue HM, S. Functions which allow to perform a full Bayesian analysis of structured additive models using Integrated Nested Laplace Approximaxion. http://www.r-inla.org/ [Accessed 25 Nov 2014]. 2009.

Hepatology

- Fong Y, Rue H, Wakefield J. Bayesian inference for generalized linear mixed models.
 Biostatistics 2010;11:397-412.
- Wandeler GS, M.; Jaquier, M-E.;Rohrbach, J.; Metzner, KJ.; Fehr, J.;Ambrosioni, J.;Cavassini, M.; Stockle, M.;Schmid, P.;Bernasconi, E.; Keiser, O.; Salazar-Vizcaya, L.;
 Furrer, H.; Rauch A. Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes between 1991 and 2013 OFID, In Press 2015;doi: 10.1093/ofid/ofv026.
- 20. The EMIS Network. EMIS 2010. The European Men-Who-Have-Sex-With-MenInternet Survey. Findings from 38 countries. Stockholm: European Centre for DiseasePrevention and Con-

trol. In; 2013.

- 21. van Sighem A, Vidondo B, Glass TR, Bucher HC, Vernazza P, Gebhardt M, de WolfF, et al. Resurgence of HIV infection among men who have sex with men in Switzerland:mathematical modelling study. PLoS One 2012;7:e44819.
- 22. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014;312:631-640.
- 23. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014;348:g3308.
- 24. European AIDS Clinical Society (EACS) Guidelines. Version 7.1. 2014.
- 25. Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, Page K, et al. HepatitisC virus clearance, reinfection, and persistence, with insights from studies of injecting drugusers: towards a vaccine. Lancet Infect Dis 2012;12:408-414.
- 26. Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 2011;274:58-66.
- 27. R Core Team (2014). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.

Hepatology

Soetaert K, Petzoldt T, Setzer RW. deSolve: General Solvers for Initial Value
 Problems of Ordinary Differential Equations (ODE), Partial Differential Equations (PDE),
 Differential Algebraic Equations (DAE), and Delay Differential Equations (DDE).
 http://cran.r-project.org/web/packages/deSolve/index.html [Accessed 25 Nov 2014] 2014.
 Soetaert K, Petzoldt T, Setzer RW. Solving Differential Equations in R: Package

deSolve. Journal of Statistical Software 2010;33:1--25.

Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, Gazzard BG,
et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive
MSM. AIDS 2013;27:2551-2557.

 Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, van der Meer JT, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 2011;25:F21-27.
 Avila D, Keiser O, Egger M, Kouyos R, Boni J, Yerly S, Klimkait T, et al. Social meets molecular: Combining phylogenetic and latent class analyses to understand HIV-1 transmission in Switzerland. Am J Epidemiol 2014;179:1514-1525.

33. Bourne AR, D.; Hickson, F.; Torres Rueda, SWP. The Chemsex study: drug use in sexual settings among gay & bisexual men in Lambeth, Southwark & Lewisham. London: Sigma Research. 2014.

34. Schmidt AJ, Falcato L, Zahno B, Burri A, Regenass S, Mullhaupt B, Bruggmann P.Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection? BMC Public Health 2014;14:3.

35. Lociciro S, Jeannin A, Dubois-Arber F. Men having sex with men serosorting with casual partners: who, how much, and what risk factors in Switzerland, 2007-2009. BMC Public Health 2013;13:839.

36. Vogel M, van de Laar T, Kupfer B, Stellbrink HJ, Kummerle T, Mauss S, Knecht G, et al. Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human

Hepatology

immunodeficiency virus-positive men who have sex with men in Germany. Liver Int 2010;30:1169-1172.

37. Witt MD, Seaberg EC, Darilay A, Young S, Badri S, Rinaldo CR, Jacobson LP, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis 2013;57:77-84.

38. Kouyos RD, Rauch A, Boni J, Yerly S, Shah C, Aubert V, Klimkait T, et al.

Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual

transmission of HCV. Int J Epidemiol 2014.

39. Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, Martin TC, et

al. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the

HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom?

Epidemiological and Modeling Insights. Clin Infect Dis 2016;62:1072-1080.

Accepted

Hepatology

Acknowledgments

Authors' contributions: LS, RDK, OK and AR designed the study. LS and RDK formulated the mathematical model. LS, CZ and GW analyzed the cohort data. LS implemented the model and performed the model analyses. GW, MB, KEAD, AC, EB, HF and PV contributed cohort data and enrolled patients. All authors contributed to the interpretation of the data and results. LS, OK, ME and AR drafted the manuscript, which was then revised by all the other authors.

The data are gathered by the five Swiss University Hospitals, two Cantonal Hospitals, 15 affiliated hospitals and 36 private physicians (listed in http://www.shcs.ch/180-health-careproviders). Members of the Swiss HIV Cohort Study: Aubert V, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the Clinical and Laboratory Committee), Fux CA, Gorgievski M, Günthard H (President of the SHCS), Haerry D (deputy of "Positive Council"), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A (Chairman of the Scientific Board), Regenass S, Rickenbach M (Head of Data Centre), Rudin C (Chairman of the Mother & Child Substudy), Schöni-Affolter F, Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S.

We thank Kali Tal for her editorial assistance.

Hepatology

Table 1. Characteristics of all MSM registered in the Swiss	HIV Cohort Study
who were included in the parameterisation of the model.	
Total number of patients	5,052
Age at registration [median(IQR)]	37 (31 - 44)
Follow up time [years, median(IQR)]	7.8 (3.6 - 14.9)
ART	
Yes	4,619 (91.4%)
Νο	433 (8.6%)
CD4 cell count at ART start [cells/µl, median(IQR)]	268 (156 -389)
Viral load at ART start [log10 copies/ml, median (IQR)]	4.8 (4.2 - 5.3)
Intravenous drug use	127 (2.5%)
Information on sexual partners	
Sex with Stable partners [N(%)]	
Yes	3,655 (72.3%)
No	1,257 (24.9%)
Refuse to answer	91 (1.80%)
Missing	49 (0.97%)
Condom use with stable partner [N(%)]	
Inconsistent	2,080 (56.9%)
Refuse to answer	29 (0.8%)
Missing	1 (0%)
Sex with occasional partners [N(%)]	
Yes	3,860 (76.4%)
No	975 (19.3%)
Refuse to answer	168 (3.3%)

Hepatology

Missing	49 (1.0%)
Condom use with occasional partner [N(%)]	
Inconsistent	1,860 (48.1%)
Refuse to answer	40 (1.0%)
Missing	2 (0.0%)
Only patients with available questionnaires on sexual partn	ers who were

followed beyond 2000 were included

ART: antiretroviral therapy

Acce

Hepatology

Table 2. Model parameters used to reproduce the incidence observed between 2000 and 2013.

Parameter	Definition	Value	Functional form	Source
ω	Rate of enrolment in care (from HIV- infection; per year)	0.45 before 2005 0.58 after 2005		Estimation using data from (21)
ρ(t)	New HCV-uninfected MSM rate ^{a,b} (individuals per year)	[135 - 257]	Splines smoothing of a series of yearly rates	SHCS
ψ(t)	Proportion of individuals with unsafe sex at entry ^c		$\begin{array}{l} 3.2 \times 10^{-2} \ if \ t < 3.8 \\ 6.1 \times 10^{-2} - 1.6 \times 10^{-2} \ t \ + 2.5 \times 10^{-3} \ t^2 \\ - \ 7.2 \times 10^{-5} \ t^3 \ if \ 0.3 < t \\ < 13.5 \end{array}$	SHCS
φ	High-risk/unsafe sex ratio	0.25		[12]
σ(t)	Rate at which individuals start to have		$4.1 \times 10^{-2} + 2 \times 10^{-3}t - 1.4 \times 10^{-3}t^2$	SHCS
	unsafe sex (per year) ^c		+ $1.2 \times 10^{-4} t^3$	
в	Infection rate (95% CI) (per year)	5.1 (4.3 – 5.7)		Fit
α	Proportion of patients who clear infection	0.53		SHCS
	after treatment ^e			[17]
η	1/average treatment duration (per year)	4/3		SHCS
λ	External force of infection x 10 ^{-3 f} (per	2.3		SHCS
C		Hepato	blogy	
	This	article is protected by co	pyright. All rights reserved.	

	year)			
μ	Exit rate (95% CI)	0.049 (0.045 - 0.053)		SHCS
γ(t), γ'(t)	Rate of treatment for each risk group (per year)	[0.02 - 0.22]	0.2/(1+e ^{-t+2006})+0.02	SHCS
S ₂₀₀₀₊ S' ₂₀₀₀ ^{b,g}	Initial number uninfected patients	1,552		SHCS
l ₂₀₀₀ ^{b,g}	Initial number of infected patients	8		SHCS
T ₂₀₀₀ ^{b,g}	Initial number of patients on treatment	0		SHCS

Abbreviations: MSM, Men who have Sex with Men; SHCS, Swiss HIV Cohort Study

^aRates were obtained applying Bayesian Poisson regression models with non-parametric smoothing priors using the R package INLA [16].

^bScaled to the HIV-infected MSM population in Switzerland assuming that 80% of all individuals in this population enrol in the SHCS.

^cThe origin is 2000.

^dRatio between the number of patients who reported frequent bondage, dominance/submission, sadism/masochism or fisting and those who reported unprotected anal intercourse with non-steady partners. The approximated ratio between patients who reported skin damage with bleeding and those who reported unprotected anal intercourse with non-steady partners is 0.23.

^eWeighted average according to time from diagnosis to treatment initiation.

^f1999-2000 average incidence rate.



Hepatology

Figure legends

Figure 1. Model structure

HCV transmission dynamics in HIV-infected MSM. Individuals are distributed in groups according to their risk behavior (without and with high-risk) and enrolment in care ("i": incare and "o": out-of-care). Individuals switch from the group without high-risk to the group with high-risk at a rate $\varphi\sigma(t)$ and from the group out-of-care to the group in-care at a rate $\omega(t)$. New individuals enter the susceptible categories (*S*) at an overall rate $\rho(t)$. A fraction $\varphi(t)$ are assigned to the high-risk group. Susceptible individuals may be infected (*I*) by an external force of infection λ that accounts for infections not acquired by contacts within the modelled population. Individuals within the high-risk group may also infect each other at an infection rate β . Individuals with spontaneous HCV-clearance remain susceptible. Infected individuals without spontaneous clearance start HCV-treatment (*T*) at a rate $\gamma(t)$. Treatment lasts on average $1/\eta$ and results in HCV-clearance for a proportion α of all treated patients. Individuals exit the system at a rate μ from all compartments.

Figure 2. High-risk recruitment parameters and HCV incidence

High-risk recruitment parameters and HCV incidence measured in the Swiss HIV Cohort Study (SHCS) between 2000 and 2013. **Panel A.** proportion of new individuals who have unprotected sex with occasional partners (unsafe sex). **Panel B.** rate at which individuals start to have unsafe sex; (black stars: observed, continuous black line: functional fit; see Table 2). The model assumed that a fraction of the patients with unsafe sex also engage in high-risk behavior, which can result in HCV transmission. **Panel C.** HCV incidence rates observed in the SHCS (green dots and error bars) and obtained with our transmission model (continuous blue line; shaded: 95% confidence intervals).

Hepatology

Figure 3. Projected HCV incidence and prevalence

Projected HCV incidence and prevalence in HIV-infected men who have sex with men (MSM) assuming that the size of the high-risk group grows (panels (A)), and health promotion or autonomous change leading to: *i*) decreasing size of the high-risk group, (panels (B)) and *ii*) decreasing size of the high-risk group (panels (C)). Two scenarios of future treatment uptake were included: 1) treatment rate constant at the average between 2006 and 2013 (22% per year, continuous lines) or 2) increased treatment rate (100% per year, dashed lines). Two treatment alternatives are displayed: Second generation DAAs regimens (red) and the current standard of care (blue). Dashed, grey, vertical lines indicate the beginning of the projection period.

Figure 4. Projected HCV incidence and prevalence in the best-case scenario of risk Behavior (A), and in all scenarios of high-risk behavior assuming treatment with DAAs with current treatment uptake (B).

Panel A. Projected HCV incidence (upper panel) and prevalence (lower panel) in HIVinfected men who have sex with men (MSM) assuming that no additional individuals enter the high-risk group and that individuals in the high-risk group transit to the group without high-risk at a rate that equals the last observed rate of transition from the group without highrisk behavior to the group with high-risk behavior. Two scenarios of future treatment uptake were included: 1) treatment rate constant at the average between 2006 and 2013 (22% per year, continuous lines) or 2) increased treatment rate (100% per year, dashed lines). Two treatment alternatives are displayed: Second generation DAAs regimens (red) and the current standard of care (blue). Dashed, grey, vertical lines indicate the beginning of the projection period. Panel B. Effect of reductions in high-risk behavior when assuming treatment with DAAs and current treatment rate.

Hepatology

(without practices leading to HCV transmission) Ľ 00 Without high-risk Infection from о external sources Enrolment Enrolment in care $\omega(t)$ $\omega(t)$ in care Treatment i λ $(1 - \alpha)\eta$ Infection from Failed treatment external sources $\alpha \eta$ Successful treatment μ Potential interventions Drop out transition to high-risk Base model : Intermediate Pessimistic Optimistic $\varphi \sigma(t)$ Best-case (with practices leading to HCV transmission) Transmission through high-risk S。 λ Infection from **High-risk** external sources Enrolment Enrolment $\omega(t)$ $\omega(t)$ in care in care Transmission through high-risk Treatment ß S li λ Infection from $(1-\alpha)\eta$ Failed treatment external sources αη Successful treatment μ Drop out

149x189mm (300 x 300 DPI)







Figure 2

209x190mm (300 x 300 DPI)

Acce

Hepatology



Figure 3

235x180mm (300 x 300 DPI)

Accept

Hepatology



Acceptec

229x124mm (300 x 300 DPI)

Hepatology

Supplementary Material

The effect of behavioural and treatment interventions to reduce hepatitis C virus transmission among HIV-infected MSM: a cohort-based modelling study

Luisa Salazar-Vizcaya¹, Roger D Kouyos², Cindy Zahnd¹, Gilles Wandeler^{1 3}, Manuel Battegay⁴, Katharine Elizabeth Ana Darling⁵, Enos Bernasconi⁶, Alexandra Calmy⁷, Pietro Vernazza⁸, Hansjakob Furrer³, Matthias Egger^{1 9}, Olivia Keiser^{*1}, Andri Rauch^{*3}, and the Swiss HIV Cohort Study

*Equal contribution

Accepted

Hepatitis C transmission model

We adopted the following system of ordinary differential equations (ODE) to model transmission of hepatitis C virus among HIV-infected men who have sex with men who do not inject drugs (see Figure 1 and heading *HCV transmission model* in the Subjects and Methods section).

$$\begin{aligned} \frac{dS'_o}{dt} &= \left(1 - \varphi\psi(t)\right)\rho(t) - \varphi\sigma(t)\max\left(0,\tilde{S}_o\right) - \omega(t)S'_o - \lambda S'_o - \mu S'_o \\ \frac{dS'_i}{dt} &= -\varphi\sigma(t)\max\left(0,\tilde{S}_i\right) + \omega(t)S'_o + \alpha\eta T' - \lambda S'_i - \mu S'_i \\ \frac{dI'_o}{dt} &= -\varphi\sigma(t)\max(0,\tilde{I}_o) - \omega(t)I'_o + \lambda S'_o - \mu I'_o \\ \frac{dI'_i}{dt} &= -\varphi\sigma(t)\max(0,\tilde{I}_i) + \omega(t)I'_o - \gamma(t)I'_i + (1 - \alpha)\eta T' + \lambda S'_i - \mu I'_i \\ \frac{dT'}{dt} &= -\varphi\sigma(t)\max\left(0,\tilde{T}\right) + \gamma(t)I'_i - \eta T' - \mu T' \end{aligned}$$

$$\text{with high - risk behaviour} \begin{cases} \frac{dS_o}{dt} = \varphi\psi(t)\rho(t) + \varphi\sigma(t)\max(0,\tilde{S}_o) - \omega(t)S_o - \frac{\beta S_o(I_o+I_i)}{\tilde{N}} - \lambda S_o - \mu S_o \\ \frac{dS_i}{dt} = \varphi\sigma(t)\max(0,\tilde{S}_i) + \omega(t)S_o - \frac{\beta S_i(I_o+I_i)}{\tilde{N}} + \alpha\eta T - \lambda S_i - \mu S_i \\ \frac{dI_o}{dt} = \varphi\sigma(t)\max(0,\tilde{I}_o) - \omega(t)I_o + \frac{\beta S_o(I_o+I_i)}{\tilde{N}} + \lambda S_o - \mu I_o \\ \frac{dI_i}{dt} = \varphi\sigma(t)\max(0,\tilde{I}_i) + \omega(t)I_o + \frac{\beta S_i(I_o+I_i)}{\tilde{N}} - \gamma(t)I_i + (1-\alpha)\eta T + \lambda S_i - \mu I_i \\ \frac{dT}{dt} = \varphi\sigma(t)\max(0,\tilde{T}) + \gamma(t)I_i - \eta T - \mu T \\ \frac{dT}{dt} = \varphi\sigma(t)\max(0,\tilde{T}) + \gamma(t)I_i - \eta T - \mu T \end{cases}$$

Where: $\tilde{N} = \theta(S'_o + S'_i + I'_o + I'_i + T') + (S_o + S_i + I_o + I_i + T)$. The transformations $\tilde{S}_o = S'_o + \frac{\varphi - 1}{\varphi} S_o$, $\tilde{I}_o = I'_o + \frac{\varphi - 1}{\varphi} I_o$, $\tilde{T} = T' + \frac{\varphi - 1}{\varphi} T$, $\tilde{S}_i = S'_i + \frac{\varphi - 1}{\varphi} S_i$ and $\tilde{I}_i = I'_i + \frac{\varphi - 1}{\varphi} I_i$ were introduced to ensure that ratio between the population in the high-risk group remains a constant proportion φ of those who would be classified to be at risk of unsafe sex. We assumed that the rate of potentially infectious contacts depends on the density of individuals with high-risk behaviour in a wider population. In this population, individuals in the group

without high-risk behaviour are weighted by the parameter $\theta \le 1$, which we term *assortativity coefficient*. Model fitting procedures led to determine the best value for this parameter to be 1. Definitions for the variables and parameters included in this model as well as a detailed description of the underlying transmission dynamics can be found in the methods section of the paper. All parameter values are shown in Table 2.

Rate of entrance of new HCV-uninfected MSM: Rates were obtained applying Bayesian Poisson regression models using the R package INLA (1, 2). The INLA method uses the Laplace approximation to perform approximate Bayesian inference. Figure S2B displays the normalize Pearson residuals for this regression. This pattern does not exhibit a trend, which suggests that the regression is unbiased.

Treatment rate 2000-2013: As described in the Methods section, we determined HCV treatment rates separately for the periods 2000-2005 and 2006-2013 because treatment uptake substantially increased between those periods in the SHCS. We used a logistic function to model this transition. The maximum value of this function was the treatment rate measured for the later period (22% per year) and the minimum value was that measured for the earlier period (2% per year). We assumed that the sigmoid's midpoint was reached in 2006 and that the steepness of the curve was 1. The resulting functional form for the treatment rate was: $\gamma(t) = \frac{0.2}{1+e^{-t+2006}} + 0.02.$

Maximum likelihood Estimation to fit the transmission model: *using HCV-incidence data from the SHCS*

We used Maximum Likelihood Estimation (MLE) to fit the infection rate β . We calculated the likelihood of patient-level incidence data given our transmission model. For this purpose, we

3

split the data and the simulation period (2000-2013) into monthly steps. For every time step we compared the incidence observed in the data with that produced using the model. Individuals who seroconvert contribute to the total likelihood L with the probability of becoming infected at their individual time of infection; and individuals who never seroconvert contribute to L with the (cumulative) probability of being uninfected at the end of their individual exposure periods.

L is then given by:

$$L = \prod_{i=1}^{n} L_i = \prod_{i=1}^{n} h(t_i)^{\delta_i} (1 - F(t_i))$$

Where: *i* indexes the *n* individuals at risk of HCV-infection; t_i is the time the individual *i* was exposed to HCV-infection; and $h(t_i)$ the evaluation of the hazard function at that time which we approximated to $\beta \frac{S_o(t_i)+S_i(t_i)}{S'_o(t_i)+S'_i(t_i)+S_o(t_i)+S_i(t_i)} \frac{I_o(t_i)+I_i(t_i)}{\tilde{N}} + \lambda$. δ_i is 1 if the individual *i* experiences the event and 0 otherwise. $F(t_i)$ is the cumulative distribution function of time to HCV infection, i.e., $F(t_i) = \int_0^{t_i} f(t) dt$, where f(t) is the probability density function of time to HCV infection.

The log-likelihood is then given by:

$$ln(L) = \sum_{i=1}^{n} \{\delta_i \ln(h(t_i)) - H(t_i)\}$$

By means of this relationship we minimised the negative log-likelihood (NLL) of observed patient-level incidence data from the SHCS data given the transmission model. The final value for β is reported in Table 2. We used a likelihood curve to estimate confidence intervals for this parameter. Figure S3 shows the likelihood curve and the corresponding confidence

interval. We performed the optimizations with the R package *optim* (3) and solved the systems of differential equations with the R package deSolve (4, 5).

Increasing *high-risk/unsafe sex ratios* led to lower estimates of the infection rate. Higher ratios also resulted in slightly improved model fits, but the maximum difference in negative log-likelihood did no exceed 0.5 (results not shown).

Uncertainty of Model Predictions

In order to assess how the uncertainty of the model parameters estimated by MLE affect the model solutions and predictions (of future HCV incidence), we used Latin Hypercube Sampling (LHS). Specifically, we sampled the infection rate β from a normal distribution that corresponds with its likelihood curve (Figure S3). We sampled the exit rate μ and the external force of infection λ from lognormal distributions depicted by the mean and the standard error estimated from the SHCS data (Table 2). We generated the sample of parameters' combinations for running the simulation model using the R package *clhs* (6) and obtained incidence predictions for each of these combinations to determine 95% confidence intervals.

Acce

Supplementary Figures

Figure S1. Structure of the "reinfection model". Super indices 2 indicate compartments associated with reinfections: Susceptible to reinfections, reinfected and on treatment for a reinfection (see also see Figure 1 in the main text).



Figure S2. A. Rate of entrance of new HCV-uninfected MSM with no history of injecting drug use calculated from the new registrations into the SHCS between 2000 and 2013 using Bayesian Poisson regression models (green dots); Smooth entry rates (solid black line, shaded: 95% confidence intervals). **B**. Normalized Pearson residuals for this regression model.



Figure S3. Likelihood curve for the infection rate (β = 5.1 (4.3 – 5.7)) fitted using MLE

(grey, dotted lines: 95% credible intervals). NLL: negative log likelihood.



Figure S4. Trends for high-risk recruitment parameters



Figure S5. Projected HCV incidence in HIV-infected men who have sex with men (MSM) for different values of the *high-risk/unsafe sex ratio* φ , assuming that the size of the high-risk group grows (panels (A)), and health promotion or autonomous change leading to: i) decreasing size of the high-risk group, (panels (B)) and ii) decreasing size of the high-risk group, (panels (B)) and ii) decreasing size of the high-risk group (panels (C)). Two scenarios of future treatment uptake were included: 1) treatment rate constant at the average between 2006 and 2013 (22% per year, continuous lines) or 2) increased treatment rate (100% per year, dashed lines). Two treatment alternatives are displayed: Second generation DAAs regimens (red) and the current standard of care (blue). Dashed, grey, vertical lines indicate the beginning of the projection period.

Acce

Figure S6. Projections assuming a protective effect of previously cleared HCV infections. Reduction in reinfection probability = 25% (similar to the assumption in [Martin, Journal of Theoretical biology, 2011]).



Supplementary tables

Table S1. Percentage of incident infections that are reinfections.

Scenario of risk behaviour	Pe	essimistic		Int	ermediate		Optimistic			
Calendar year	2015	2020	2030	2015	2020	2030	2015	2020	2030	
IFN + current treatment uptake	3.6%	16.5%	44.0%	3.6%	24.6%	44.5%	3.6%	33.9%	58.8%	
DAAs + current treatment uptake	3.6%	26.6%	58.1%	3.6%	36.0%	56.9%	3.6%	45.9%	66.1%	
IFN + higher treatment uptake	3.6%	22.3%	57.0%	3.6%	30.5%	44.6%	3.6%	36.3%	31.6%	
DAAs + higher treatment uptake	3.6%	26.2%	57.0%	3.6%	32.6%	23.3%	3.6%	35.4%	7.6%	

Table S2. Changes in high-risk behaviour.

	Increase in proportion with high-								
	risk behaviour*								
Scenario of high behaviour	5-year increase	15-year increase							
Pessimistic	75%	184%							
Intermediate	-2%	4%							
Optimistic	-26%	-58%							

* with respect to the value in 2015

Negative increase means decrease

Table S3. Sensitivity analysis on the external force of high-risk related HCV-infections

(imported infections).

A. Incidence per 100 person-years (2030)

Scenario of risk behaviour		Pessimistic					Intermediate					
Percentage of imported infections*	3% (Main model)	6%	12%	27%	3% (Main model)	6%	12%	27%	3% (Main model)	6%	12%	27%
IFN + current treatment uptake	10.7	10.5	9.9	8.6	2.3	2.2	2.1	1.9	0.6	0.6	0.6	0.5
DAAs + current treatment uptake	13.7	13.3	12.3	10.1	2.8	2.8	2.6	2.1	0.7	0.7	0.7	0.6
IFN + higher treatment uptake	10.4	9.6	8.0	4.8	1.6	1.5	1.3	1.0	0.4	0.4	0.4	0.4
DAAs + higher treatment uptake	8.5	7.1	4.6	2.3	0.5	0.6	0.6	0.7	0.2	0.3	0.3	0.4

B. Prevalence (2030)												
Scenario of risk behaviour		Pessimistic			Inte	rmediat	Optimistic					
Percentage of imported infections*	3% (Main model)	6%	12%	27%	3% (Main model)	6%	12%	27%	3% (Main model)	6%	12%	27%
IFN + current treatment uptake	39.9%	39.2%	37.7%	33.6%	13.6%	13.4%	12.8%	11.4%	6.1%	6.0%	5.8%	5.4%
DAAs + current treatment uptake	36.8%	36.0%	34.1%	29.1%	11.7%	11.3%	10.6%	8.8%	4.5%	4.4%	4.2%	3.7%
IFN + higher treatment uptake	23.1%	21.6%	18.4%	11.8%	4.9%	4.5%	3.9%	3.1%	1.5%	1.5%	1.5%	1.5%
DAAs + higher treatment uptake	11.0%	9.3%	6.3%	3.3%	0.9%	0.9%	1.0%	1.1%	0.4%	0.4%	0.5%	0.6%

*Percentage of all incident infections in de high-risk population in care in 2013.

Table S4. Sensitivity analysis assuming a protective effect of previously cleared HCV infections.

A. Incidence per 100 person-years (2030)

Scenario of risk behaviour	Pessimistic				Intern	Optimistic						
Reduction in reinfection probability*	0% (Main model)	13%	25%	50%	0% (Main model)	13%	25%	50%	0% (Main model)	13%	25%	50%
IFN + current treatment uptake	10.7	10.5	10.3	9.5	2.3	2.2	2.2	2.0	0.6	0.6	0.5	0.5
DAAs + current treatment uptake	13.7	13.2	12.6	10.9	2.8	2.7	2.6	2.1	0.7	0.7	0.6	0.5
IFN + higher treatment uptake	10.4	9.5	8.6	6.4	1.6	1.4	1.2	0.9	0.4	0.3	0.3	0.3
DAAs + higher treatment uptake	8.5	6.9	5.5	3.4	0.5	0.5	0.4	0.3	0.2	0.2	0.2	0.2

B. Prevalence (2030)

Scenario of risk behaviour	Pessimistic				Inter	Optimistic						
Reduction in reinfection probability*	0% (Main model)	13%	25%	50%	0% (Main model)	13%	25%	50%	0% (Main model)	13%	25%	50%
IFN + current treatment uptake	39.9%	39.4%	38.8%	37.1%	13.6%	13.4%	13.1%	12.2%	6.1%	5.9%	5.7%	5.2%
DAAs + current treatment uptake	36.8%	36.0%	35.0%	31.9%	11.7%	11.2%	10.7%	9.3%	4.5%	4.3%	4.0%	3.3%
IFN + higher treatment uptake	23.1%	21.6%	20.0%	16.1%	4.9%	4.4%	3.9%	3.0%	1.5%	1.4%	1.3%	1.1%
DAAs + higher treatment uptake	11.0%	9.2%	7.6%	5.0%	0.9%	0.8%	0.7%	0.6%	0.4%	0.4%	0.4%	0.4%

* with respect to first infection

References

1. Rue HM, S. Functions which allow to perform a full Bayesian analysis of structured additive models using Integrated Nested Laplace Approximation. http://www.r-inla.org/ [Accessed 25 Nov 2014]. 2009.

2. Fong Y, Rue H, Wakefield J. Bayesian inference for generalized linear mixed models. Biostatistics 2010;11:397-412.

3. General-purpose Optimization optim {stats}. The R Project for Statistical Computing. https://stat.ethz.ch/R-manual/R-devel/library/stats/html/optim.html [Accessed 25 Nov 2014].

4. Soetaert K, Petzoldt T, Setzer RW. deSolve: General Solvers for Initial Value Problems of Ordinary Differential Equations (ODE), Partial Differential Equations (PDE), Differential Algebraic Equations (DAE), and Delay Differential Equations (DDE). http://cran.r-project.org/web/packages/deSolve/index.html [Accessed 25 Nov 2014] 2014.

5. Soetaert K, Petzoldt T, Setzer RW. Solving Differential Equations in R: Package deSolve. Journal of Statistical Software 2010;33:1--25.

6. Roudier P. clhs: Conditioned Latin Hypercube Sampling. http://cran.rproject.org/web/packages/clhs/index.html [Accessed 25 Nov 2014] 2014.

Acce